Developer docs
API playgroundTry for free, no card

Search company profiles

DyAnsys

Full company profile

uuid000hrl1

Namestring
DyAnsys
Legal namestring
DyAnsys Inc.
Websiteurl
dyansys.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

DyAnsys is a privately held medical device company founded in 2015 and headquartered in Silicon Valley, California, that develops and sells FDA-cleared auricular neurostimulation devices and autonomic nervous system (ANS) monitoring equipment. The company focuses on the under-served area of ANS measurement and non-narcotic pain and addiction therapy, serving healthcare providers across multiple specialties including pain management, addiction treatment, endocrinology/diabetology, anesthesiology, and cardiology.

The company's product portfolio rests on two underlying technology platforms: (i) percutaneous auricular neurostimulation — including percutaneous electrical nerve stimulation (PENS) and percutaneous electrical nerve field stimulation (PNFS) — which delivers low-level electrical pulses via needles placed in ear nerve endings to trigger endorphin release, embodied in the Primary Relief, Drug Relief, and First Relief devices; and (ii) ANS diagnostics via the ANSiscope, which measures heart rate variability (HRV) from ECG-derived R-R intervals to quantify parasympathetic/sympathetic balance. Diagnostic ECG hardware is sold under the ECScope brand. Multiple FDA clearances across distinct indications — opioid withdrawal (2018), diabetic peripheral neuropathy (2022), and post-operative pain following C-section and cardiac surgery (2022) — and a proprietary HRV algorithm validated on over 100,000 patients underwrite the IP base, with First Relief and ANSiscope patented in the USA and other jurisdictions.

DyAnsys operates a hybrid go-to-market: disposable single-use devices are sold primarily through an authorized global distributor network (with European distribution channeled through wholly-owned DyAnsys Europe SARL in Switzerland), alongside direct sales to hospitals, surgical centers, pain clinics, and addiction treatment facilities. Manufacturing is conducted through DyAnsys India Private Ltd, a wholly-owned subsidiary. Pricing is quote-based and not publicly disclosed, and revenue streams are concentrated in hardware sales of regulated medical devices. No revenue figures, funding rounds, or headcount are disclosed; the company appears to be founder/management-owned under CEO Srini Nageshwar.

Short descriptiontext

DyAnsys is a privately held medical device company that develops and sells FDA-cleared auricular neurostimulation devices and autonomic nervous system monitoring equipment to healthcare providers across pain management, addiction treatment, diabetic care, anesthesiology, and cardiology specialties.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurostimulation medical devices, pain management devices, autonomic nervous system monitoring, FDA-cleared neuromodulation, electrocardiogram equipment
Industry3 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
SECONDARYHLAKAIAN
Autonomic Disorders (Dysautonomia)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Devices (Neuromodulation and Diagnostics)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

DyAnsys generates revenue from the sale of FDA-cleared neurostimulation medical devices including Primary Relief, First Relief, and Drug Relief. Devices are single-use/disposable and sold in packages (e.g., Drug Relief 5 per box). Sold through distributors and directly to healthcare providers.

dyansys.com
2ECG Equipment Sales
TypeHardware Sales
Description

DyAnsys markets a line of electrocardiogram (ECG) machines designed for doctor's offices and hospital settings, sold as medical diagnostic equipment.

dyansys.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1First Relief
Description

FDA-cleared percutaneous electrical neurostimulation (PENS) device for symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy, cleared for multiple treatments up to 56 days

dyansys.com
+4 more records
Core offering1 text field

DyAnsys develops and sells FDA-cleared auricular neurostimulation medical devices that deliver low-level electrical pulses through needles placed in the ear to stimulate nerve endings and trigger endorphin release for non-narcotic pain management and opioid withdrawal aid. Its portfolio includes Primary Relief® (post-operative pain), Drug Relief® (opioid withdrawal), First Relief® (diabetic peripheral neuropathy), the ANSiscope® autonomic nervous system monitor, and ECScope 100™ electrocardiogram equipment for clinical settings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Mean fentanyl dosage as rescue analgesic in post-operative period was only one-third of control group in clinical trial
+3 more records
Product overview1 text field

DyAnsys provides a portfolio of advanced medical diagnostic and monitoring systems, centered on autonomic nervous system (ANS) measurement and neurostimulation therapy. The product lineup consists of five core offerings: ANSiscope®, a diagnostic HRV-based ANS monitoring device used for measuring autonomic dysfunction; ECScope 100™, an electrocardiogram machine for clinical settings; and three percutaneous electrical neurostimulation (PENS/PNFS) devices — Primary Relief® (for post-operative pain including cardiac surgery and C-section), First Relief® (for diabetic neuropathic pain), and Drug Relief® (for opioid withdrawal aid). All three neurostimulation devices are wearable, ear-worn devices that deliver electrical pulses through needles inserted at auricular nerve endings. The company also provides a Testing System used by distributors to verify proper functioning of neurostimulator devices.

Product and service5 records
1Primary Relief®
CategoryNeurostimulation medical device (post-operative pain)
Description

A percutaneous electrical neurostimulation (PENS) device worn behind the ear that delivers continuous low-level electrical pulses through ear nerve endings for up to 72 hours, providing symptomatic relief of post-operative pain following cardiac surgery and C-section delivery for hospitals and surgical centers.

2Drug Relief®
CategoryNeurostimulation medical device (opioid withdrawal aid)
Description

A percutaneous electrical nerve field stimulator (PNFS) placed behind the ear with tiny needles inserted in ear nerve endings, sending continuous electrical pulses over 120 hours to reduce symptoms of opioid withdrawal during detoxification for addiction treatment centers and physicians managing opioid dependency.

3First Relief®
CategoryNeurostimulation medical device (diabetic neuropathic pain)
Description

A percutaneous electrical neurostimulation (PENS) device applied behind the ear that delivers continuous pulses of low-level electrical current, FDA-cleared for multiple treatments up to 56 days for symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy for pain management physicians and diabetologists.

4ANSiscope®
CategoryAutonomic nervous system diagnostic device
Description

An autonomic nervous system (ANS) monitoring device that measures parasympathetic and sympathetic system activity with every heartbeat through heart rate variability (HRV) analysis from ECG-derived R-R intervals, providing specific measurements of autonomic dysfunction and sympathovagal balance for diabetologists, endocrinologists, and clinical researchers.

5ECScope 100™
CategoryElectrocardiogram diagnostic equipment
Description

A line of electrocardiogram (ECG) machines designed for doctor's office and hospital settings, featuring high sensitivity without excessive filtering techniques that could mask subtle cardiac problems, marketed as an affordable diagnostic option for primary care and cardiology practices.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

NeuroMetrix is a small-cap medical device company that markets wearable neurostimulation devices (e.g., Quell for chronic pain, DPNCheck for diabetic peripheral neuropathy). It is a direct peer to DyAnsys in percutaneous/wearable electrical neurostimulation for diabetic neuropathy and chronic pain, targeting overlapping HCP and patient populations.

TypeDirect peer
Description

ElectroCore makes non-invasive vagus nerve stimulation (nVNS) devices, including gammaCore for headache/migraine and other indications. It is a direct peer to DyAnsys in non-pharmacologic, device-based neuromodulation for pain and neurological indications, using electrical stimulation through cutaneous/auricular access points.

TypeDirect peer
Description

SPR Therapeutics markets SPRINT PNS, a minimally invasive peripheral nerve stimulation system for acute and chronic pain. It is a direct peer to DyAnsys in percutaneous, short-duration peripheral neurostimulation for post-operative and chronic pain management.

TypeBroad incumbent
Description

Medtronic is a global medical device leader with broad neuromodulation franchises including spinal cord stimulators, deep brain stimulators, and targeted drug delivery for chronic pain. It is a broad incumbent competing with DyAnsys across multiple pain and addiction indications with much larger commercial scale.

TypeBroad incumbent
Description

Boston Scientific operates a sizable Neuromodulation division (spinal cord stimulators, WaveWriter, Vertis, etc.). It is a broad incumbent in the same clinical pain categories where DyAnsys competes, though with implant-based rather than percutaneous/wearable systems.

TypeBroad incumbent
Description

Abbott (formerly St. Jude Medical) sells Proclaim DRG and other neuromodulation systems for chronic pain. It is a broad incumbent competing for hospital and pain clinic budgets allocated to neurostimulation-based pain therapy.

TypeEmerging player
Description

IHS (now part of Spark Biomedical) markets the NSSysta/BRIDGE auricular neurostimulation device and has been used in opioid withdrawal and pain management protocols. It is an emerging player targeting the same auricular/PNFS niche as DyAnsys' Drug Relief.

TypeEmerging player
Description

Cefaly Technology makes an external trigeminal nerve stimulation device (Cefaly device) for migraine prevention and acute treatment. It is an emerging player in non-invasive peripheral neurostimulation for pain with overlapping neurology referral channels.

TypeEmerging player
Description

Axonics Modulation Technologies develops and markets sacral neuromodulation systems (snm systems) for overactive bladder, urinary retention, and fecal incontinence. It is an emerging player in implant-based neurostimulation that competes for HCP relationships and payer formulary attention adjacent to DyAnsys' area.

TypeOthers
Description

Masimo is a patient monitoring and pulse oximetry company whose signal extraction technology underpins many ECG and HRV-based monitors. It is an adjacent/oth ers peer to DyAnsys' ANSiscope HRV-based autonomic monitoring franchise, supplying enabling technology and competing indirectly in clinical monitoring budgets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DyAnsys

Medical Devices (Neuromodulation and Diagnostics)dyansys.com

DyAnsys is a privately held medical device company that develops and sells FDA-cleared auricular neurostimulation devices and autonomic nervous system monitoring equipment to healthcare providers across pain management, addiction treatment, diabetic care, anesthesiology, and cardiology specialties.

What DyAnsys does

DyAnsys is a privately held medical device company founded in 2015 and headquartered in Silicon Valley, California, that develops and sells FDA-cleared auricular neurostimulation devices and autonomic nervous system (ANS) monitoring equipment. The company focuses on the under-served area of ANS measurement and non-narcotic pain and addiction therapy, serving healthcare providers across multiple specialties including pain management, addiction treatment, endocrinology/diabetology, anesthesiology, and cardiology.

The company's product portfolio rests on two underlying technology platforms: (i) percutaneous auricular neurostimulation — including percutaneous electrical nerve stimulation (PENS) and percutaneous electrical nerve field stimulation (PNFS) — which delivers low-level electrical pulses via needles placed in ear nerve endings to trigger endorphin release, embodied in the Primary Relief, Drug Relief, and First Relief devices; and (ii) ANS diagnostics via the ANSiscope, which measures heart rate variability (HRV) from ECG-derived R-R intervals to quantify parasympathetic/sympathetic balance. Diagnostic ECG hardware is sold under the ECScope brand. Multiple FDA clearances across distinct indications — opioid withdrawal (2018), diabetic peripheral neuropathy (2022), and post-operative pain following C-section and cardiac surgery (2022) — and a proprietary HRV algorithm validated on over 100,000 patients underwrite the IP base, with First Relief and ANSiscope patented in the USA and other jurisdictions.

DyAnsys operates a hybrid go-to-market: disposable single-use devices are sold primarily through an authorized global distributor network (with European distribution channeled through wholly-owned DyAnsys Europe SARL in Switzerland), alongside direct sales to hospitals, surgical centers, pain clinics, and addiction treatment facilities. Manufacturing is conducted through DyAnsys India Private Ltd, a wholly-owned subsidiary. Pricing is quote-based and not publicly disclosed, and revenue streams are concentrated in hardware sales of regulated medical devices. No revenue figures, funding rounds, or headcount are disclosed; the company appears to be founder/management-owned under CEO Srini Nageshwar.

DyAnsys firmographics

Firmographics
Name
DyAnsys
Legal name
DyAnsys Inc.
Website
https://dyansys.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
DyAnsys is a privately held medical device company that develops and sells FDA-cleared auricular neurostimulation devices and autonomic nervous system monitoring equipment to healthcare providers across pain management, addiction treatment, diabetic care, anesthesiology, and cardiology specialties.
Ownership category
akta.pro rank

DyAnsys industry classification

Industry
Product category
Medical Devices (Neuromodulation and Diagnostics)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
SECONDARYHLAKAIAN
Autonomic Disorders (Dysautonomia)

Keywords

  • Neurostimulation medical devices
  • Pain management devices
  • Autonomic nervous system monitoring
  • FDA-cleared neuromodulation
  • Electrocardiogram equipment

Where DyAnsys is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Offices3 records

Markets served

DyAnsys business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: DyAnsys generates revenue from the sale of FDA-cleared neurostimulation medical devices including Primary Relief, First Relief, and Drug Relief. Devices are single-use/disposable and sold in packages (e.g., Drug Relief 5 per box). Sold through distributors and directly to healthcare providers.
  2. ECG Equipment Sales: DyAnsys markets a line of electrocardiogram (ECG) machines designed for doctor's offices and hospital settings, sold as medical diagnostic equipment.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

DyAnsys product offering

Product offering

Core offering

DyAnsys develops and sells FDA-cleared auricular neurostimulation medical devices that deliver low-level electrical pulses through needles placed in the ear to stimulate nerve endings and trigger endorphin release for non-narcotic pain management and opioid withdrawal aid. Its portfolio includes Primary Relief® (post-operative pain), Drug Relief® (opioid withdrawal), First Relief® (diabetic peripheral neuropathy), the ANSiscope® autonomic nervous system monitor, and ECScope 100™ electrocardiogram equipment for clinical settings.

Product overview

DyAnsys provides a portfolio of advanced medical diagnostic and monitoring systems, centered on autonomic nervous system (ANS) measurement and neurostimulation therapy. The product lineup consists of five core offerings: ANSiscope®, a diagnostic HRV-based ANS monitoring device used for measuring autonomic dysfunction; ECScope 100™, an electrocardiogram machine for clinical settings; and three percutaneous electrical neurostimulation (PENS/PNFS) devices — Primary Relief® (for post-operative pain including cardiac surgery and C-section), First Relief® (for diabetic neuropathic pain), and Drug Relief® (for opioid withdrawal aid). All three neurostimulation devices are wearable, ear-worn devices that deliver electrical pulses through needles inserted at auricular nerve endings. The company also provides a Testing System used by distributors to verify proper functioning of neurostimulator devices.

Differentiator

Problem solved

Functional benefit

Brands

  • First Relief: FDA-cleared percutaneous electrical neurostimulation (PENS) device for symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy, cleared for multiple treatments up to 56 days
  • Primary Relief
  • Drug Relief
  • ANSiscope
  • ECScope 100

Products and services

  • Primary Relief® A percutaneous electrical neurostimulation (PENS) device worn behind the ear that delivers continuous low-level electrical pulses through ear nerve endings for up to 72 hours, providing symptomatic relief of post-operative pain following cardiac surgery and C-section delivery for hospitals and surgical centers.
  • Drug Relief® A percutaneous electrical nerve field stimulator (PNFS) placed behind the ear with tiny needles inserted in ear nerve endings, sending continuous electrical pulses over 120 hours to reduce symptoms of opioid withdrawal during detoxification for addiction treatment centers and physicians managing opioid dependency.
  • First Relief® A percutaneous electrical neurostimulation (PENS) device applied behind the ear that delivers continuous pulses of low-level electrical current, FDA-cleared for multiple treatments up to 56 days for symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy for pain management physicians and diabetologists.
  • ANSiscope® An autonomic nervous system (ANS) monitoring device that measures parasympathetic and sympathetic system activity with every heartbeat through heart rate variability (HRV) analysis from ECG-derived R-R intervals, providing specific measurements of autonomic dysfunction and sympathovagal balance for diabetologists, endocrinologists, and clinical researchers.
  • ECScope 100™ A line of electrocardiogram (ECG) machines designed for doctor's office and hospital settings, featuring high sensitivity without excessive filtering techniques that could mask subtle cardiac problems, marketed as an affordable diagnostic option for primary care and cardiology practices.

Quantifiable outcome

  • Mean fentanyl dosage as rescue analgesic in post-operative period was only one-third of control group in clinical trial
  • +3 more outcomes

Companies that use DyAnsys

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles5 records

DyAnsys technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

DyAnsys partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

DyAnsys competitors and assessment

Company assessment

Direct peers

  • NeuroMetrix: NeuroMetrix is a small-cap medical device company that markets wearable neurostimulation devices (e.g., Quell for chronic pain, DPNCheck for diabetic peripheral neuropathy). It is a direct peer to DyAnsys in percutaneous/wearable electrical neurostimulation for diabetic neuropathy and chronic pain, targeting overlapping HCP and patient populations.
  • ElectroCore: ElectroCore makes non-invasive vagus nerve stimulation (nVNS) devices, including gammaCore for headache/migraine and other indications. It is a direct peer to DyAnsys in non-pharmacologic, device-based neuromodulation for pain and neurological indications, using electrical stimulation through cutaneous/auricular access points.
  • SPR Therapeutics: SPR Therapeutics markets SPRINT PNS, a minimally invasive peripheral nerve stimulation system for acute and chronic pain. It is a direct peer to DyAnsys in percutaneous, short-duration peripheral neurostimulation for post-operative and chronic pain management.

Broad incumbents

  • Medtronic: Medtronic is a global medical device leader with broad neuromodulation franchises including spinal cord stimulators, deep brain stimulators, and targeted drug delivery for chronic pain. It is a broad incumbent competing with DyAnsys across multiple pain and addiction indications with much larger commercial scale.
  • Boston Scientific: Boston Scientific operates a sizable Neuromodulation division (spinal cord stimulators, WaveWriter, Vertis, etc.). It is a broad incumbent in the same clinical pain categories where DyAnsys competes, though with implant-based rather than percutaneous/wearable systems.
  • Abbott: Abbott (formerly St. Jude Medical) sells Proclaim DRG and other neuromodulation systems for chronic pain. It is a broad incumbent competing for hospital and pain clinic budgets allocated to neurostimulation-based pain therapy.

Emerging players

  • Innovative Health Solutions: IHS (now part of Spark Biomedical) markets the NSSysta/BRIDGE auricular neurostimulation device and has been used in opioid withdrawal and pain management protocols. It is an emerging player targeting the same auricular/PNFS niche as DyAnsys' Drug Relief.
  • Cefaly: Cefaly Technology makes an external trigeminal nerve stimulation device (Cefaly device) for migraine prevention and acute treatment. It is an emerging player in non-invasive peripheral neurostimulation for pain with overlapping neurology referral channels.
  • Axonics: Axonics Modulation Technologies develops and markets sacral neuromodulation systems (snm systems) for overactive bladder, urinary retention, and fecal incontinence. It is an emerging player in implant-based neurostimulation that competes for HCP relationships and payer formulary attention adjacent to DyAnsys' area.

Others

  • Masimo: Masimo is a patient monitoring and pulse oximetry company whose signal extraction technology underpins many ECG and HRV-based monitors. It is an adjacent/oth ers peer to DyAnsys' ANSiscope HRV-based autonomic monitoring franchise, supplying enabling technology and competing indirectly in clinical monitoring budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

DyAnsys social profiles

Digital presence

DyAnsys compliance and trust

Trust signal

Compliance1 record

DyAnsys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DyAnsys leadership team

Management profile

Number of profiles

Profiles1 record

DyAnsys subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

DyAnsys funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DyAnsys M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DyAnsys

What does DyAnsys do?

DyAnsys develops and sells FDA-cleared auricular neurostimulation medical devices that deliver low-level electrical pulses through needles placed in the ear to stimulate nerve endings and trigger endorphin release for non-narcotic pain management and opioid withdrawal aid. Its portfolio includes Primary Relief® (post-operative pain), Drug Relief® (opioid withdrawal), First Relief® (diabetic peripheral neuropathy), the ANSiscope® autonomic nervous system monitor, and ECScope 100™ electrocardiogram equipment for clinical settings.

Is DyAnsys a public or private company?

DyAnsys is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DyAnsys founded?

DyAnsys was founded in 2015. It employs 11 to 50 people.

Where is DyAnsys based?

DyAnsys is headquartered in San Mateo, United States, in the North America region.

How does DyAnsys make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are ECG Equipment Sales.

Who are DyAnsys's main competitors?

Direct peers on record are NeuroMetrix, ElectroCore and SPR Therapeutics. Broad incumbents are Medtronic, Boston Scientific and Abbott. Emerging players are Innovative Health Solutions, Cefaly and Axonics. Masimo is listed as an others.

Does DyAnsys have an API?

No public API is recorded for DyAnsys.

What industry is DyAnsys in?

DyAnsys's product category is Medical Devices (Neuromodulation and Diagnostics). Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessLineA device to decipher body signalsDyAnsys, a medical device company co-founded by Srini Nageshwar and Melvyn Lafitte, manufactures wearable devices that treat conditions such as chronic pain and opioid withdrawal using autonomic nervous system signals. The company recently received FDA approval for its auricular neurosimulation device to aid in reducing opioid withdrawal symptoms without narcotics, following earlier clearance for pain management applications. While the firm generates revenue from selling approximately 10,000 units annually to US doctors, it faces challenges scaling in the US market and seeks greater banking support for startups in India.PR NewswireFDA Clears DyAnsys Neurostimulation Device Primary Relief to Treat C-Section PainDyAnsys, Inc. announced that its FDA-cleared Primary Relief device is approved for treating post-operative pain following Caesarean sections. The wearable neurostimulation device provides symptomatic relief for up to three days by delivering electrical pulses to the ear, serving as an opioid-free alternative. Clinical studies indicated that the device reduced pain scores faster than standard analgesics without requiring additional opioids or causing adverse events.FierceBiotechFDA OKs wearable neurostimulator from DyAnsys to treat pain from diabetic nerve damageThe FDA cleared DyAnsys' First Relief wearable neurostimulator for treating pain from diabetic neuropathy. The device uses three needles behind the ear to emit electrical pulses, with a study showing significant pain score reductions lasting at least 90 days. No adverse reactions were reported.PR NewswireFDA Clears DyAnsys Neurostimulation Device First Relief to treat Diabetic Neuropathic PainDyAnsys Inc. announced FDA clearance for its First Relief PENS (percutaneous electrical neurostimulation) device to provide symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy for treatments up to 56 days. The wearable device, applied behind the ear, delivers continuous low-level electrical pulses and was approved based on a clinical study at Jeevak Multispeciality Hospital in Warangal, India, involving 63 patients that demonstrated significant reduction in pain scores with no adverse events observed. The company, headquartered in California with subsidiaries in Switzerland and India, described the clearance as a significant non-drug treatment option for patients with diabetic neuropathy.GlobeNewswireDyAnsys Inc. Recruits Distributors for Non-Narcotic Chronic Pain Treatment SolutionDyAnsys Inc. announced plans to add distributors to sell its ANSiStim pain-relief device in the United States. The FDA-cleared system uses low-level electrical pulses to treat chronic pain and is being sought in one to three states. The company seeks distributors reselling medical devices to pain treatment practitioners.